Lexaria Bioscience Extends Agreement with PharmaCO to 2026
Lexaria Bioscience provided this update on the Material Transfer Agreement originally entered into on August 30, 2024 with a pharmaceutical company to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development results related to GLP-1. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams. Over the past 12 months, Lexaria has taken important steps in advancing its GLP-1 development program. This includes recently announced progress in each of its 2026 R&D studies: Human Study #7; Animal Study #1; and Animal Study #2. All of these studies are within the GLP-1 sector and have been designed with the goal of providing fulsome evidence to better allow additional collaboration and potential licensing of Lexaria's technology. Each of the studies mentioned above are in process and are fully funded with existing corporate resources. Results are expected during Q3 and Q4 of this calendar year.
